Back to Previous Page
New SearchHide Search
CTL019 targets a protein called CD19 and is the first investigational chimeric antigen receptor T-cell (CAR-T) therapy identified for development under the Penn-Novartis alliance.
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.
You are here
This site is intended for a global audience.